HARMONY BIOSCIENCES

Q3 2024

Financial Results and Business Updates

October 29, 2024

NASDAQ LISTED HRMY

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," "may," "could," "might," "continue," "potential," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on current expectations or objectives that are inherently uncertain. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expressed or implied forwarding-looking statements, including, but not limited to the risk factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the SEC. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Innovative, Patient Focused, and Catalyst-Rich Portfolio

$1B+

Proven commercial product and growing

$3B+

Establishing leadership position in CNS

13

Development programs; 4 in Phase 3 by year end

5

Anticipate 1 or more new product or indication launches each year over next 5 years

Catalyst-rich pipeline poised to deliver both near-term and long-term value creation

SLEEP/ WAKE

Extending Our Leadership Position

- Compelling new data; conviction in IH - sNDA on track for Q4 2024
- Next-generation formulations of pitolisant to extend franchise beyond 2040
- Potential best-in-class orexin-2 agonist (BP1.15205)

NEURO BEHAVIORAL

Next Major Clinical Catalyst

- Pivotal Phase 3 trial in Fragile X syndrome; topline data on track for mid-2025
- Plan to initiate pivotal Phase 3 trial in 22q deletion syndrome in 2025

EPILEPSY

Most Advanced 5-HT2 Development Program

- EPX-100: validated MOA
- Pivotal registrational trial in Dravet syndrome; topline data in 2026
- Pivotal Phase 3 trial in Lennox-Gastaut syndrome to initiate Q4
- EPX-200: proven and confirmed MOA

Innovation driving growth of the portfolio

HARMONY BIOSCIENCES

Harmony Biosciences data on file.

WAKIX® Net Revenue Performance



HIGHLIGHTS

- **Durable double-digit sales growth** continuing into year five on the market
- **Passed $2B in cumulative net revenue since launch**
- Underlying demand drove continued revenue growth
  - Strong patient interest
  - Continue to add new prescribers and grow WAKIX prescriber base

Reiterating Full Year Guidance of $700-$720M

Confident in WAKIX being a potential $1B+ opportunity in narcolepsy alone

HARMONY BIOSCIENCES

Meaningfully Differentiated Product Profile Key Driver in Strong Durable Growth in Patients on WAKIX®



Q3 24 Highlights

~6,800 Average number of patients on WAKIX and growing

On our way to a $1B+ opportunity in adult narcolepsy

More unique prescribers of WAKIX® than sodium oxybate

Strong market access coverage (>80%) – *even with the availability of generic and new oxybate options*

1. Net Patient Additions based on previously disclosed quarterly average number of patients on WAKIX

HARMONY BIOSCIENCES

Unique Prescriber Dynamics Support Continued WAKIX® Growth, Opportunity for Next-Gen Pitolisant Assets in Narcolepsy

~9,000 NARCOLEPSY TREATING HCPs

~4,000
Enrolled in oxybate REMS

WAKIX growth

↑ **Depth of prescribing**

~5,000
Not enrolled in oxybate REMS

WAKIX growth

Breadth of prescribing

MORE UNIQUE PRESCRIBERS OF WAKIX THAN SODIUM OXYBATE

Unique feature as non-scheduled treatment is the highest performing driver and differentiator for WAKIX[1]

Growing prescriber base for WAKIX with access to full diagnosed patient opportunity

1. Harmony Market Research, May 2024

HARMONY BIOSCIENCES

The Pitolisant Franchise: Patient-Centric Drug Development Building Our Leadership Position in Sleep/Wake



1. McCullough et al. Novel treatment options in narcolepsy, Chicago Rush Memorial Center - SLEEP 2019 Abstract; 2. Droogleever et al. (2012). Severe fatigue in narcolepsy with cataplexy. Sleep, 21(2), 163-169; 3. Barateau et al., Dauvilliers, 2019; 4. Wang et al., 2023; 4. Zhan et al., 2023; 5. Postmarketing study; 6. Versta Research, Know Narcolepsy Survey ("Know Narcolepsy"), October 2018; * WAKIX attributes based on FDA-approved adult narcolepsy product labelling.

HARMONY BIOSCIENCES

Pitolisant Franchise Poised to Drive Durable Patient and Revenue Growth to the Mid-2040s



- Two meaningfully differentiated product profiles building off WAKIX with PDUFAs prior to LOE
- Provisional patents filed out to 2044 to extend durable patient and net revenue growth
  - Pursuing other indications (IH, DM1) to drive incremental patient, net revenue growth

- **Pitolisant franchise strengthens leadership position in sleep/wake**
- **Poised to deliver durable patient growth and significant revenue to the mid 2040s**

*Based on pediatric exclusivity

HARMONY BIOSCIENCES

Harmony Biosciences: R&D Pipeline



3 CNS FRANCHISES

8 ASSETS

13 DEVELOPMENT PROGRAMS

4 PHASE 3 PROGRAMS BY YEAR END

HARMONY BIOSCIENCES

Idiopathic Hypersomnia: Strong Benefit/Risk Proposition

IH: DISORDER WITH HIGH UNMET NEED

REAL WORLD DATA
Experience from a large clinic & Compassionate Use program

FAVORABLE BENEFIT/RISK PROFILE

COMPELLING TOTALITY OF DATA FROM INTUNE STUDY
a Phase 3 pivotal study in IH

ESTABLISHED SAFETY
Non-scheduled and simple dosing regimen

On-track for sNDA submission in 4Q 2024

HARMONY BIOSCIENCES

OX2R Agonist BP1.15205: Potential Best-in-Class Asset

Potent on-target effects

High potency with potential efficacy in various sleep disorders and other indications

Highly desirable QD dosing

Potentially better AE profile

Potential approval in early 2030s

Potential for combination drug development:

pitolisant-HD and BP1.15205

Potential best-in-class OX2R agonist with possibility for broad clinical utility; on track for IND submission mid-2025

Epilepsy Franchise: Deliver Meaningful Treatment Options to Patients with Serious Unmet Medical Needs

ACQUISITION OF EPYGENIX
EPX-100 AND EPX-200

POTENTIAL FOR FAVORABLE
risk/benefit proposition

ON TRACK
to initiate EPX-100 Phase 3 study in Lennox-Gastaut syndrome (LGS) in Q4 2024

EPX-100 and EPX-200:
Established serotonergic (5HT2) MoA

EPX-100: LEAD INDICATION IN DRAVET SYNDROME (DS)
Pivotal registrational study on track for topline data in 2026

Epilepsy Franchise: Most Advanced and Promising Development Programs in DEEs

- **EPX-100 (clemizole hydrochloride)**
  - Established serotonergic (5-HT2) mechanism of action
  - Pre-clinical evidence for efficacy supporting broad utility in DEEs
  - BID dosing and liquid formulation: Clinically relevant for patients with DEEs and their caregivers
  - Two decades on market in 1960's/70's with no safety signals; Promising preliminary safety and tolerability profile from ongoing Phase 3 registrational trial in DS
  - On-track for DS Topline data in 2026
  - On-track to initiate Phase 3 registrational trial in LGS by end of 2024
  - Granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for both DS & LGS

- **EPX-200 (liquid formulation of lorcaserin)**
  - Established serotonergic (5-HT2) mechanism of action; selective 5-HT2C agonist
  - Pre-clinical and clinical evidence for efficacy
  - Safety and tolerability from short- and long-term studies
  - Pre-IND stage of development
  - Granted ODD for DS in US and EU; ODD and RPDD for LGS in US

EPX-100 (Clemizole HCl): Overview and Clinical Development Programs

EPX-100 or Clemizole HCl once marketed as a 1st generation antihistamine in the 1960s

Sunsetted in 1970s with the introduction of newer antihistamines — no significant post-marketing safety signals



Development as an NCE, including completion of preclinical studies prior to human clinical trials[1]

No additional cardiac or lab monitoring necessary

Modulation of serotonin signal (5HT2A/2B/2C)[2]
established MoA for DEE

Supported by published work from Dr. Baraban et al. at UCSF, funded by NIH[3]

Phase 1 study in Healthy Volunteers completed[1]

Ongoing Phase 3 study in DS; initiation of Phase 3 study in LGS in Q4 2024, IP to 2038

- **Established MoA; potential for favorable risk/benefit profile in DEEs**
- **On track for topline data in DS and LGS in 2026**
- **EPX-100 granted ODD and RPDD for both DS and LGS**

1. Harmony data on file; 2. Griffin et al Brain, 2017; 3. Baraban et al Nature Communications, 2019.

EPX-100: Preliminary Safety and Tolerability Data Compared to Select Approved Drugs in DS and LGS

	Epidiolex[1]	Fintepla[2]	EPX-100[3]
Decreased appetite	16–22%	8%	0%
Diarrhea	9–20%	6%	16%
Somnolence	23–25%	11%	12%
LFT monitoring	Required	n/a	n/a
REMS (CVD and PAH)	n/a	+	n/a
Echocardiography	n/a	Prior to initiation and every 6 months thereafter	n/a

CVD: cardiac valvular disease
PAH: pulmonary arterial hypertension

Does not represent Head-to-Head comparison

EPX-100: Preliminary safety/tolerability profile suggests no need for additional lab or cardiac monitoring; potential for favorable risk/benefit profile

1. Epidiolex PI: AEs in patients treated with Epidiolex in clinical trials; 2. Fintepla PI: MC AEs in >5% of patients and more than placebo in placebo-controlled trials; 3. Harmony Biosciences data on file.

EPX-200 (liquid lorcaserin): Overview

EPX-200: Safety and tolerability established in short- and long-term studies

Liquid formulation and BID dosing

Selective 5HT-2C Agonist[1]
established MoA for DEEs

Supported by published work from Dr. Baraban et al. at UCSF, funded by NIH[2]

Clinical data in DEEs[3]

Pre-IND

- **Established MoA; potential for favorable risk/benefit profile in DEEs**
- **Pre-IND stage of development**
- **EPX-200 granted ODD for DS in US and EU; ODD and RPDD for LGS in US**

1. Griffin et al Brain Communications, 2019; 2. Baraban et al Nature Communications, 2019.; 3 Tolete, Devinsky et al, Neurology 2018

Financial Highlights

(In millions, USD)

Net Product Revenue



Non-GAAP Adjusted Net Income(1)

Cash, Cash Equivalents & Investments



(1) Non-GAAP Adjusted Net Income= GAAP Net Income excluding non-cash interest expense, depreciation, amortization, stock-based compensation, other non-operating items and tax effect of these items

HARMONY BIOSCIENCES

Financial Summary

(In millions, USD) Totals may not foot due to rounding	Three Months Ended September 30,		% Change	Nine Months Ended September 30,		% Change
	2024	2023		2024	2023	
Net Product Revenue	**$186.0**	**$160.3**	**16%**	**$513.5**	**$413.6**	**24%**
Cost of Product Sold	42.8	32.3	32.5%	102.4	78.1	31%
Total Operating Expenses	**$81.6**	**$63.5**	**29%**	**$276.0**	**$183.7**	**50%**
R&D Expense (1)	25.4	17.5	45%	111.2	45.8	143%
S&M Expense	27.6	23.4	18%	83.3	70.5	18%
G&A Expense	28.6	22.5	27%	81.5	67.4	21%
Net Income	**$46.1**	**$38.5**	**20%**	**$96.0**	**$102.2**	**(6%)**
Cash, cash equivalents & investments	**$504.7**					

NM denotes not meaningful % change
(1) Includes upfront licensing fee of $25.5M related to the 2024 Bioprojet Sublicense Agreement and IPR&D charge of $17.1M related to the acquisition of Epygenix for the nine months ended September 30, 2024

GAAP vs NON-GAAP Reconciliation

(In millions, USD) Totals may not foot due to rounding	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
GAAP net income	**$46.1**	**$38.5**	**$96.0**	**$102.2**
Non-cash interest expense(1)	0.2	2.2	0.5	3.1
Depreciation	0.0	0.1	0.3	0.4
Amortization(2)	6.0	6.0	17.9	17.9
Stock-based compensation expense	11.5	8.0	32.9	22.3
Licensing fee and milestone payments(3)	1.0	-	26.5	0.8
Loss on debt extinguishment(6)	-	9.8		9.8
Transaction related costs(4)	-	-	17.1	-
Income tax effect related to Non-GAAP adjustments(5)	(5.1)	(5.7)	(20.2)	(11.0)
Non-GAAP adjusted net income	**$59.6**	**$58.8**	**$170.9**	**$145.4**
GAAP net income per diluted share	**$0.79**	**$0.63**	**$1.66**	**$1.68**
Non-GAAP adjusted net income per diluted share	**$1.03**	**$0.97**	**$2.96**	**$2.39**
Weighted average number of shares of common stock used in non-GAAP diluted per share	58,103,963	60,681,676	57,754,016	60,892,992

(1) Includes amortization of deferred finance charges.
(2) Includes amortization of intangible asset related to WAKIX.
(3) Amount represents upfront licensing fee incurred upon closing the 2024 Bioprojet Sublicense Agreement and milestones related to HBS102 in September 2024 and March 2023.
(4) Includes IPR&D charge related to the acquisition of Epygenix.
(5) Calculated using the reported effective tax rate for the periods presented less impact of discrete items.
(6) ncludes loss on extinguishment of the Blackstone Credit Agreement.

DELIVER ON PROMISE TO PATIENTS

Commitment to patients

Addressing unmet medical needs

Delivering meaningful treatment options

Helping patients thrive

DELIVER STONG VALUE TO SHAREHOLDERS

Innovative

Catalyst-rich pipeline

Profitable biotech company

Meaningful investment opportunity

THANK YOU

HARMONY BIOSCIENCES

company/harmonybiosciences/ @harmonybio harmony_biosciences

www.harmonybiosciences.com